| Quarter (USD) | Sep 24 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 274.27 mm | 274.27 mm | 274.27 mm | 274.27 mm | 274.27 mm | |
| Cash burn (monthly) | (no burn) | (no burn) | 11.85 mm | 5.76 mm | 3.67 mm | |
| Cash used (since last report) | n/a | n/a | 33.09 mm | 16.09 mm | 10.26 mm | |
| Cash remaining | n/a | n/a | 241.18 mm | 258.18 mm | 264.02 mm | |
| Runway (months of cash) | n/a | n/a | 20.3 | 44.8 | 71.8 | |
| 13F holders | Current |
|---|---|
| Total holders | 53 |
| Opened positions | 35 |
| Closed positions | 12 |
| Increased positions | 6 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 106.23 bn |
| Total shares | 51.62 mm |
| Total puts | 59.30 k |
| Total calls | 300.20 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Redmile | 15.27 mm | $48.25 bn |
| HPWH TH | 7.45 mm | $275.20 mm |
| Orbimed Advisors | 4.32 mm | $13.64 bn |
| Oaktree Capital Group Holdings GP | 4.28 mm | $19.01 mm |
| AZN AstraZeneca | 4.01 mm | $0.00 |
| MS Morgan Stanley | 2.97 mm | $9.37 bn |
| Auven Therapeutics | 2.23 mm | $11.09 mm |
| Silverarc Capital Management | 1.77 mm | $5.59 bn |
| BAC Bank of America | 1.22 mm | $3.84 bn |
| Artal | 1.02 mm | $3.22 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 11 Dec 24 | Redmile | Common Shares, par value CHF 0.08 per share | Buy | Acquire P | No | No | 3.81 | 50,000 | 190.50 k | 13,145,712 |
| 11 Dec 24 | Redmile | Common Shares, par value CHF 0.08 per share | Buy | Acquire P | No | No | 2.28 | 50,000 | 114.00 k | 13,095,712 |
| 11 Dec 24 | Redmile | Common Shares, par value CHF 0.08 per share | Buy | Acquire P | Yes | No | 3.81 | 50,000 | 190.50 k | 15,666,731 |
| 11 Dec 24 | Redmile | Common Shares, par value CHF 0.08 per share | Buy | Acquire P | Yes | No | 2.28 | 50,000 | 114.00 k | 15,616,731 |
| 6 Dec 24 | Ameet Mallik | Common Shares | Payment of exercise | Dispose F | No | No | 3.13 | 238,343 | 746.01 k | 929,005 |
| 6 Dec 24 | Graham Peter J | Common Shares | Payment of exercise | Dispose F | No | No | 3.13 | 41,458 | 129.76 k | 188,542 |
| 6 Dec 24 | Jose Carmona | Common Shares | Payment of exercise | Dispose F | No | No | 3.13 | 48,108 | 150.58 k | 301,892 |
| 6 Dec 24 | Lisa Michelle Kallebo | Common Shares | Payment of exercise | Dispose F | No | No | 3.13 | 6,503 | 20.35 k | 35,997 |
